Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction
- PMID: 25739854
- DOI: 10.1002/cncr.29297
Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction
Abstract
Background: Malignant bowel obstruction affects an estimated 3% to 15% of patients with cancer, with a mean survival of <4 weeks reported in patients with inoperable malignant bowel obstruction. In the current study, the authors assessed predictors of survival and the influence of treatment modality in US patients with cancer who were hospitalized for malignant bowel obstruction.
Methods: All the US cancer patients hospitalized with malignant bowel obstruction in 2006 and 2010 were included. Data were obtained from the Nationwide Inpatient Sample provided by the Agency for Healthcare Research and Quality. Malignant bowel obstruction diagnoses and treatment variables were identified using Clinical Classifications Software codes based on International Classification of Diseases, Ninth Revision and Current Procedural Terminology codes. Univariate and multivariate analyses were performed with a logistic model, weighted chi-square test, and a generalized linear model.
Results: The authors identified 942,014 and 1,103,528 hospitalizations for malignant bowel obstruction in 2006 and 2010, respectively. Medical management, upper gastrointestinal obstruction, health insurance coverage, and obesity were found to be significantly associated with better hospital survival. Multivariate analysis also demonstrated significantly increased odds of death with male sex, advanced age, AJCC stage IV disease, multiple comorbid conditions (except acquired immunodeficiency syndrome), and weight loss. There were no significant differences with stratification based on the location and etiology of the obstruction (primary tumor vs metastatic).
Conclusions: Malignant bowel obstruction is a common cause of death in hospitalized patients with advanced cancer in the United States. The odds of death are especially high in older patients and those with concurrent medical illnesses. Lack of insurance coverage, significant weight loss, and surgical management also appear to be associated with higher mortality in this population.
Keywords: hospital data; malignant bowel obstruction; patients with cancer; predictors of survival; treatment modality.
© 2015 American Cancer Society.
Similar articles
-
Predictors of adverse surgical outcome in the management of malignant bowel obstruction.Rev Invest Clin. 2008 May-Jun;60(3):212-6. Rev Invest Clin. 2008. PMID: 18807733
-
Outcomes of small bowel obstruction in patients with previous gynecologic malignancies.Am J Surg. 2012 Apr;203(4):472-9. doi: 10.1016/j.amjsurg.2011.07.013. Epub 2011 Dec 15. Am J Surg. 2012. PMID: 22172316
-
Predictive factors of early bowel obstruction in colon and rectal surgery: data from the Nationwide Inpatient Sample, 2006-2008.J Am Coll Surg. 2012 May;214(5):831-7. doi: 10.1016/j.jamcollsurg.2012.01.044. Epub 2012 Mar 28. J Am Coll Surg. 2012. PMID: 22464661
-
Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.J Support Oncol. 2004 Jul-Aug;2(4):323-34; discussion 334-7. J Support Oncol. 2004. PMID: 15357517 Review.
-
[Intestinal occlusion in cancer].Rev Gastroenterol Mex. 2004 Nov;69 Suppl 3:100-5. Rev Gastroenterol Mex. 2004. PMID: 16881208 Review. Spanish.
Cited by
-
The impact of rurality on racial disparities in costs of bowel obstruction treatment.Surg Open Sci. 2024 May 29;20:27-31. doi: 10.1016/j.sopen.2024.05.012. eCollection 2024 Aug. Surg Open Sci. 2024. PMID: 38873333 Free PMC article.
-
Colorectal Cancer-The "Parent" of Low Bowel Obstruction.Medicina (Kaunas). 2023 May 2;59(5):875. doi: 10.3390/medicina59050875. Medicina (Kaunas). 2023. PMID: 37241107 Free PMC article. Review.
-
Racial Disparities in Surgery for Malignant Bowel Obstruction.Ann Surg Oncol. 2022 May;29(5):3122-3133. doi: 10.1245/s10434-021-11161-0. Epub 2022 Jan 18. Ann Surg Oncol. 2022. PMID: 35041096
-
Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites.J Int Med Res. 2021 Feb;49(2):300060520986664. doi: 10.1177/0300060520986664. J Int Med Res. 2021. PMID: 33616416 Free PMC article. Clinical Trial.
-
The Value of Haematological Parameters and Tumour Markers in the Prediction of Intestinal Obstruction in 1474 Chinese Colorectal Cancer Patients.Dis Markers. 2020 Aug 14;2020:8860328. doi: 10.1155/2020/8860328. eCollection 2020. Dis Markers. 2020. PMID: 32855747 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
